Biovie (BIVI) Interest Expenses (2013 - 2026)
Biovie (BIVI) posted Interest Expenses of $365967.0 for Q1 2026, up 179.93% sequentially from $130734.0 in Q4 2025, and up 189.73% YoY from $126313.0 in Q1 2025.
Biovie (BIVI) Interest Expenses (2013 - 2026) Analysis & Trends
Biovie has reported Interest Expenses for 14 years, with the latest figure at $365967.0 in Q1 2026.
- Quarterly Interest Expenses rose 189.73% year-over-year to $365967.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $365967.0 (up 189.73% YoY) and the FY2025 annual result came in at $74.9 million, up 7.61% from the prior year.
- Interest Expenses grew to $365967.0 in Q1 2026 per BIVI's latest filing, from $130734.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $1.6 million in Q2 2022 and troughed at $4998.0 in Q2 2025.
- A 5-year average of $661161.8 and a median of $629000.0 in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2025: Interest Expenses surged 4859.42% in 2022, then tumbled 98.86% in 2025.
- Over 5 years, Interest Expenses stood at $1.1 million in 2022, then slipped by 25.4% to $820600.0 in 2023, then plunged by 91.87% to $66700.0 in 2024, then surged by 96.0% to $130734.0 in 2025, then jumped by 179.93% to $365967.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $365967.0, $130734.0, and $426814.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Biovie | 14.17 Mn | 14.17 Mn | - | 3,978.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,978.00 |
| Jun 30, 2026 | 3,978.00 |
| Mar 31, 2026 | 365,967.00 |
| Mar 31, 2026 | 365,967.00 |
| Dec 31, 2025 | 130,734.00 |
| Dec 31, 2025 | 130,734.00 |
| Sep 30, 2025 | 426,814.00 |
| Sep 30, 2025 | 426,814.00 |
| Jun 30, 2025 | 4,998.00 |
| Jun 30, 2025 | 4,998.00 |
| Mar 31, 2025 | 126,313.00 |
| Mar 31, 2025 | 126,313.00 |
| Dec 31, 2024 | 66,700.00 |
| Dec 31, 2024 | 66,700.00 |
| Sep 30, 2024 | 256,024.00 |
| Sep 30, 2024 | 256,024.00 |
| Jun 30, 2024 | 439,943.00 |
| Jun 30, 2024 | 439,943.00 |
| Mar 31, 2024 | 629,000.00 |
| Mar 31, 2024 | 629,000.00 |